Engflag

Ofia

Quick links to important sections

Ofia

Ofia_EN

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ofia

Property Description
Active ingredient Ofloxacin
Form Tablet, Solution (Ophthalmic/Otic), IV Solution
Pharmacological class Quinolone antibiotic
General purpose Manages bacterial infections
Origin Synthetic compound

What Type of Medicine is Ofia (Ofloxacin)?

Ofia is a trade name for the active pharmaceutical ingredient Ofloxacin, which is a synthetic compound classified pharmacologically as a quinolone antibiotic. This specific compound is further categorized as a second-generation fluoroquinolone, a designation that is clinically recognized for its improved activity spectrum compared to earlier classes.

This classification is significant because it defines Ofloxacin as a broad-spectrum antimicrobial agent that is chemically engineered, rather than naturally derived. Ofloxacin is utilized to treat bacterial infections in various parts of the body. Ofia is typically designated as a prescription-only medication, reflecting its potent and specific nature within pharmaceutical treatment protocols and targeting a broad adult patient group.

Composition and Available Forms of Ofloxacin

The active ingredient in Ofia is Ofloxacin, which functions as a single-ingredient product, typically prepared as Ofloxacin hydrochloride. The drug is manufactured in several distinct dosage forms to facilitate both targeted and systemic administration.

The available forms include oral tablets for systemic treatment, and sterile aqueous solutions designed for highly specific, localized use via topical routes. These topical forms are specifically formulated as an ophthalmic solution for the eye and an otic solution for the ear, alongside an intravenous solution for parenteral delivery when immediate or intensive systemic action is required. This multi-form availability is a key differentiating factor, confirming Ofloxacin's flexibility in treating either widespread or highly localized infections.

What is Ofloxacin's General Therapeutic Purpose?

The general therapeutic purpose of Ofloxacin is to act as a bactericidal agent, meaning it is designed to kill susceptible bacteria responsible for causing illness. It achieves this by directly interfering with the bacteria's critical processes required for genetic function.

Unlike agents that only slow bacterial growth, Ofloxacin directly blocks the ability of bacterial cells to maintain, repair, and replicate their DNA, effectively eliminating the pathogen. The drug is used for its antibacterial activity across a wide range of susceptible organisms. This mechanism of action provides the general benefit of managing infections caused by a broad spectrum of bacteria, such as those affecting the urinary tract or skin structure.

What side effects are possible with Ofia?

Possible Side Effects and Safety Information

Ofloxacin (Ofia), as a fluoroquinolone class antibiotic, is associated with a distinct safety profile documented in official regulatory labeling. This profile includes the recognition of serious, disabling, and potentially irreversible adverse reactions affecting multiple organ systems.

Serious and Clinically Significant Reactions

Regulatory warnings highlight risks involving the musculoskeletal and nervous systems. These include tendinitis which may progress to tendon rupture, an event that can occur within the first 48 hours of starting treatment or several months after stopping therapy. Peripheral neuropathy, characterized by pain, burning, tingling, or weakness, is also documented and may be long-lasting. Central nervous system effects such as seizures and serious psychiatric reactions (including confusion, hallucinations, and suicidal thoughts) have been reported, sometimes following the first dose.

Other serious documented effects include aortic aneurysm and dissection and QT interval prolongation (an electrical abnormality of the heart). Metabolic risks, such as severe hypoglycemia (low blood sugar) that can potentially lead to coma, are also noted.

Common and System-Based Adverse Reactions

Reactions most frequently classified as common in official labeling include nausea, diarrhea, headache, dizziness, and insomnia. Officially listed adverse effects are organized by the physiological system affected, which include:

  • Gastrointestinal Disorders: Nausea, Diarrhea, Vomiting.
  • Nervous System Disorders: Headache, Dizziness, Insomnia.
  • Skin and Subcutaneous Tissue Disorders: Photosensitivity or phototoxicity (increased skin sensitivity to light).

Population-Specific Safety Considerations

Specific safety considerations are documented for certain groups. Older adults (over 60 years) are at an increased risk for tendon injury and aortic complications. Patients with renal impairment or those who have received solid organ transplants also face a heightened risk of tendon injury. Furthermore, patients with diabetes are at a higher risk of developing blood glucose disturbances (dysglycemia).

Overdose and Emergency Response

An overdose of Ofloxacin (Ofia) is officially documented in regulatory labeling to present with specific clinical manifestations that indicate acute systemic toxicity. These regulator-listed symptoms include neurological effects such as drowsiness, slurred speech, confusion, and dizziness. Other documented signs can include nausea, hot and cold flushes, and numbness or swelling of the face.

The official labeling emphasizes the potential for severe systemic toxicity, necessitating urgent medical intervention. Serious outcomes can involve the Central Nervous System (CNS), with documented risks of convulsions (seizures) and increased intracranial pressure. Cardiac risk is also noted due to the potential for QT interval prolongation. Furthermore, acute toxicity may trigger life-threatening events like severe acute hypersensitivity reactions.

It is mandated in official documents that individuals must seek immediate medical attention for an overdose. Urgent medical help is required for any signs of a severe reaction, including the first onset of a seizure or severe allergic response. Management of an overdose is symptomatic and supportive, as no specific antidote is known. Procedures focus on providing supportive care and ensuring airway maintenance if clinically necessary. Regulatory documents also note that elderly subjects and patients with impaired renal function face a higher risk of drug accumulation and toxicity due to slower elimination.

Therapeutic Uses of Ofia

What Ofia Treats: Main Uses and Benefits

Ofia is commonly used across conditions presenting with acute episodes marked by heightened distress. It is considered relevant across therapeutic domains involving the lower respiratory tract, urinary and genital tracts, and for skin and external manifestations.

The medication helps address symptom clusters that may become intense or disruptive, such as fever, painful urination (dysuria), and symptoms related to redness or discharge in localized sites. It is commonly used across domains where additional symptomatic support is needed in conditions such as pyelonephritis, acute exacerbations of chronic bronchitis, pelvic inflammatory disease (PID), and acute conjunctivitis.

“The medication provides support that helps ease the overall symptom burden when symptoms become temporarily overwhelming.”

Quick Fact: Relief for Systemic and Localized Discomfort

Used in settings marked by temporary physiological imbalance, it supports the patient during difficult episodes by easing distress. The medication is relevant for easing symptoms that interfere with daily comfort across the airways, urogenital system, and external sensory organs, assisting with maintaining functional stability during symptomatic periods.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Official Eligibility and Contraindications for Ofia (Ofloxacin)

Official regulatory documents define the populations permitted, restricted, or prohibited from using systemic Ofloxacin. The medicine is contraindicated and must not be used in patients with:

  • Hypersensitivity to Ofloxacin or any other fluoroquinolone antibiotic.
  • A history of tendon disorders related to previous fluoroquinolone use.
  • A diagnosis of epilepsy or any existing central nervous system condition that lowers the seizure threshold.
  • Myasthenia Gravis (use should be avoided as symptoms can be exacerbated).

Age and Reproductive Restrictions

Systemic Ofloxacin is contraindicated for use in pregnant women and those who are breastfeeding. It is also contraindicated in children and growing adolescents (typically under 18 years of age) for systemic use (oral/IV). In contrast, localized forms, such as the otic solution (ear drops), are approved for use in pediatric patients as young as six months.

Conditional Use and Special Caution

The medicine is permitted for use in adults and older adults, though caution is advised for patients over 60, as they have an increased risk of tendon injury. Special consideration is also required for patients with:

  • Impaired Renal Function (kidney disease), which necessitates mandatory dosage adjustment.
  • Cardiac Risk Factors, such as a history of prolonged QT interval or uncorrected low potassium (hypokalemia).
  • Concurrent Corticosteroid Use or a history of organ transplantation, as these factors increase the risk of tendon injury.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ofia (Ofloxacin) has officially documented interaction patterns that necessitate administration restrictions or monitoring, as defined by regulatory authorities.

Interaction Type Interacting Agents / Classes Restriction or Outcome
Reduced Absorption Magnesium/aluminum-containing Antacids, Sucralfate, Iron Salts, Zinc Preparations, Didanosine (chewable/buffered) Oral Ofloxacin must not be taken within two hours before or after administration of these agents to prevent reduced serum concentration.
Altered Clearance Probenecid, Cimetidine, Furosemide, Methotrexate These agents decrease the total clearance of Ofloxacin, officially resulting from competition for active transport at the renal tubular excretion site.
Pharmacodynamic Effects Theophylline, certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Co-administration may cause a pronounced lowering of the cerebral seizure threshold.
Cardiac Risk Class IA and III Antiarrhythmics, Macrolides, Tricyclic Antidepressants, Antipsychotics Used with caution due to the formally documented increased risk of QTc prolongation (additive effect).
Monitoring Required Vitamin K Antagonists (e.g., Warfarin), Glibenclamide Coagulation tests (PT/INR) must be monitored due to a possible increase in the effect of Warfarin. Patients receiving Glibenclamide require close monitoring for possible hypoglycemia.

The regulatory profile defines strict conditions for concurrent use to manage risks related to systemic exposure and additive pharmacodynamic effects. Food consumption does not affect Ofloxacin's total exposure, though the time to reach maximum concentration (Tmax) is officially prolonged. The interaction structure emphasizes mandatory timing separation for chelation-forming products and requires close physiological monitoring for agents affecting coagulation or blood sugar levels.

Mechanism of Action

Targeted Inhibition of Bacterial Genomic Maintenance

Ofia (Ofloxacin) acts as an intracellular inhibitor by targeting two essential bacterial enzymes: DNA Gyrase and Topoisomerase IV. The drug's mechanism is defined by its ability to trap these enzymes in a complex with the bacterial DNA, preventing the necessary re-ligation of DNA strands. This molecular interference disrupts the bacteria’s ability to manage its genetic material.

Induction of Lethal Bactericidal Cascades

The trapping action causes a rapid and irreversible accumulation of DNA double-strand breaks (DSBs) within the bacterial cell, initiating a lethal bactericidal cascade. This damage halts DNA replication, transcription, and repair, which prevents the bacterial cell from successfully completing its growth and the final step of binary fission. The resulting physiological effect is the direct elimination of susceptible bacterial populations, which is the physiological consequence of the cellular destruction.

️ Mechanisms Limiting Effectiveness

The effectiveness of the mechanism is constrained by bacterial defenses, which primarily include mutations in the target enzymes (DNA Gyrase and Topoisomerase IV) that reduce Ofloxacin's binding affinity. Additionally, the overexpression of efflux pumps allows the bacteria to actively transport the drug out of the cell, functionally circumventing the mechanism by preventing Ofloxacin from reaching its necessary intracellular concentration.

Dosage and Administration Information

How to Use Ofia

Ofia (Ofloxacin) is administered according to strict dosage protocols for both systemic and localized treatment. The medicine is available for systemic use as Oral Tablets and Intravenous (IV) Solution, and for localized application as Topical Ophthalmic and Otic Solutions.

Labeled Administration Parameters

Instruction Domain Official Guideline/Rule
Route & Form Oral Tablets, IV Solution, Topical Ophthalmic/Otic Solution
Standard Dosing Systemic daily doses range from 200 mg to 800 mg, with a maximum of 800 mg daily.
Frequency Systemic courses are typically administered twice daily (every 12 hours); some regimens require once daily administration.
Duration The course length varies, ranging from short 3-day courses up to a maximum systemic duration of 2 months for certain indications.

Contextual Usage Principles

Systemic administration must adhere to specific rules regardless of the indication. Oral tablets can be taken with or without food. For daily doses greater than 400 mg, the total amount must be divided into two separate administrations. When administered intravenously, a 400 mg dose is infused over a duration of 60 minutes.

Specific dose adjustments are required for patients with impaired organ function. A dosage modification is necessary for patients with renal impairment (CrCl le 50 mL/min), often reducing the frequency to once daily. Similarly, for patients with severe hepatic impairment, the maximum daily dose should not exceed 400 mg.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ofia

Official research for Ofia (Ofloxacin) was evaluated in specific clinical studies focusing on bacterial infections across different body systems. The research base primarily consists of short-term, randomized controlled trials (RCTs) and multicenter studies. These trials are designed to compare Ofloxacin against an inactive treatment (placebo) or other treatments used in the research context. These studies monitored outcomes related to systemic or functional imbalance, such as tracking the clearance of bacteria and how symptoms evolved.

Evidence for Use in Systemic Infections (Urinary and Respiratory Tracts)

For serious infections like complicated urinary tract infections (UTIs), including pyelonephritis, Ofloxacin was evaluated in studies alongside other treatments used in the research context. The research examined adult populations, including older subjects, focusing on outcomes related to physical discomfort. Studies described measurements of bacterial clearance rates when Ofloxacin was observed alongside other treatments. Research also examined Ofloxacin's use in lower respiratory tract infections, monitoring changes in symptoms like cough and sputum production. Studies reported how symptoms evolved in the observed populations, and the measured clinical response data was documented alongside data from comparator antibiotics.

Evidence for Use in Localized Infections (Eye and Ear)

For infections of the eye, such as bacterial conjunctivitis, the solution was evaluated in specialized trials where some patients received the active medicine and others received an inactive liquid (vehicle). Findings describe patterns observed in the research where the measured resolution of visible infection signs was tracked when Ofloxacin was observed alongside the inactive vehicle. The otic (ear) solution was studied for conditions like acute otitis externa (swimmer's ear) in both adults and children, tracking changes in ear pain and discharge. Studies describe patterns related to the evolution of symptoms and the clearance of common ear pathogens.

What the Evidence Base Indicates is Still Uncertain

A primary limitation across the evidence base is the ongoing and evolving challenge of antimicrobial resistance, which may affect how reliably Ofloxacin can be used against certain bacteria over time. Furthermore, most efficacy trials are primarily short-term, limited to observing short-term changes in bacterial status shortly after therapy ends. Research has not fully established the long-term effects or the durability of the effect for preventing future acute episodes. Findings describe group patterns, not personal outcomes.

Key Studies & References

  1. Ofloxacin: NIH StatPearls

How should Ofia be stored and disposed of?

How to Store and Dispose of Ofia (Ofloxacin)

The official labeling mandates specific conditions for storing and handling Ofloxacin to preserve its stability and effectiveness.

Storage Requirements

Condition Requirements as per Regulatory Labeling
Temperature Tablets and IV Solution: Store at controlled room temperature, typically 20 C to 25 C. Topical Solutions: Store between 15 C and 25 C.
Protection Keep from freezing; the medicine must be stored away from excessive heat, moisture, and direct light.
Packaging Keep the medicine in its original container, and ensure the container remains tightly closed when not in use.
Child Safety Ofloxacin must be stored out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Ofloxacin should be disposed of via a drug take-back program whenever available. Regulatory guidelines advise against flushing Ofloxacin down the toilet. If a take-back option is unavailable, the product should be mixed with an unpalatable substance and sealed in a bag before being placed in the household trash, following official recommendations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ofia found in:

A-Z Index: